Please try another search
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Name | Age | Since | Title |
---|---|---|---|
Garo H. Armen | 69 | 2017 | Executive Chairman |
Brian J. Corvese | 64 | 2017 | Independent Director |
Barbara A. Ryan | 62 | 2021 | Independent Director |
Jennifer Buell | 46 | 2021 | President, CEO & Director |
Ulf Arne Wiinberg | 65 | 2017 | Independent Director |
Lydia Lynch | - | - | Member of the Scientific Advisory Board |
Peter Behner | 59 | 2021 | Independent Director |
Manuel Hidalgo | 55 | - | Member of the Scientific Advisory Board |
Robert Benjamin Stein | 72 | - | Member of the Scientific Advisory Board |
Mark A. Exley | - | - | Member of the Scientific Advisory Board |
Marcela V. Maus | 46 | - | Member of the Scientific Advisory Board |
Jenny Gumperz | - | - | Member of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review